The Small Cap to Large Cap Batton Pass

Good morning, Armchair Army,

Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.

Every small stock starts with a group of investors carrying it.

Founders. Retail investors. Small-cap funds willing to get in early.

The believers.

But hopefully, one day, the company will grow…

Build credibility (hit some milestones) and attract the next group of investors willing to carry it forward.

Companies CAN outgrow their original shareholder base.

This is a good thing.

I call it… the great baton pass.

Getting this baton pass right is critical to the company's long-term success.

A big cap raise to the right investors… at the right time.

More trading volume.

More liquidity.

And finally…

Index inclusion.

Passive money flows into the stock.

Early investors flow out.

Index inclusion is the cornerstone of any great bottom pass.

This is because once a company reaches the index, ETFs and funds that track the index must own the stock.

Late Friday night, the S&P Dow Jones Index announced its quarterly rebalance.

In healthcare, here is what moved in:

In healthcare, here is what moved out:

Index inclusion is the market equivalent to a full moon.

Strange things happen.

Massive buying (or selling) from index funds and ETFs mandated to hold a basket of stocks in an index…

… and the arbitrage hedge funds “betting” on the index inclusion.

When I woke up this morning (having written much of this article), I realised the AFR wrote about this exact topic last night… spooky.

So, what happens around index time?

Hedge funds positioning for a stock falling out of the index…

Here are the short positions of Cochlear and Sonic Healthcare (anticipating this happening):

On the flip side…

Hedge funds anticipating a stock entering an index…

Someone asked me yesterday why PYC Therapeutics has run up over the last few weeks.

I think that this positioning for index inclusion is one of the reasons.

… but there is one more thing that happens when a stock enters the index that is not immediately obvious.

Short positions rise.

Why?

Because stock borrowing is now available to short sellers.

Vanguard, BlackRock, State Street and the local index trackers buy the stock ahead of inclusion and put it straight into their lending programs.

I wrote about this earlier this year with 4DMedical:

BEFORE index inclusion… the short interest in 4DX had never climbed above 0.6%.

Then the stock was announced as an index inclusion.

The lendable float went from "trace" to tens of millions.

Almost overnight, short sellers appeared.

Thursday, 19 March: 3.1 million shares short.

Friday, 20 March: 17.3 million shares short.

An extra 14.2 million shares in one day.

4DX is now the third most shorted stock on the ASX.

… and it is a similar story for many healthcare stocks that graduate into the ASX-300 or ASX 200.

Mesoblast. Clarity. Telix. Clinuvel. Polynovo.

All sit among the 15 most shorted stocks on the ASX.

So…

For any small-cap stock, index inclusion is one of the great baton-passing moments.

A graduation from small-cap minnow to the big leagues.

But the big leagues bring new challenges.

Passive buyers enter the arena.

… and with them comes a new group of arbitrage funds trading around those passive flows.

Buying and selling because of the index - not the fundamentals of the business.

These games are out of the company’s control.

You know what isn’t?

Execution.

Hit milestones → Beat expectations → Repeat.

That’s the game any company can play.

Whether the company is down in the microcap land or in the ASX-200.

Nothing can replace good old execution.

Let’s dive in…

Clever Culture Systems (ASX: CC5) secures a purchase order from Novo Nordisk for two additional APAS Independence instruments. (CC5)

🪑 Nice “expand” deal with a tier-1 customer.

CONNEQT Health (ASX: CQT) secures a marketing and distribution agreement with Blueprint for its Pulse Arterial Health Monitor. (CQT)

🪑 Nice deal.

Blueprint is the longevity medicine website founded by tech entrepreneur Bryan Johnson.

EBR Systems (ASX: EBR) Santa Clara facility secures ISO 13485 certification, increasing production capacity for its WiSE pacemaker by 500%. (EBR)

Aroa Biosurgery (ASX: ARX) publishes the interim results from a prospective study using its bioscaffolding product on soft tissue reconstruction. It reported only a 0.7% deep tissue infection rate in 411 patients. (ARX)

🪑 The MYRIAD product is already registered and in use by surgeons, so this study is more of a marketing exercise than a registrational trial.

Good results still.

ReNerve (ASX: RNV) and RMIT receive a $500k government grant for a nerve regeneration project focusing on post-prostate surgery applications. (RNV)

Neurizon Therapeutics (ASX: NUZ) appoints Dr Chris Bremer as CEO. (NUZ)

🪑 With over US$1 billion in executed licencing transactions, it’s clear to see what specialty NUZ was looking for in a CEO.

Dimerix (ASX: DXB) has secured a total of A$34 million in a non-dilutive loan facility to fund key clinical milestones, with potential to extend up to A$50 million. (DXB)

🪑 This puts any questions about a capital raise for Dimerix to bed.

The company will now advance its new kidney asset through a Phase 2 clinical trial, and will have plenty of cash runway to get through to the Phase 3 data readout in the first half of 2028.

I will note that repayment is still scheduled for Jan 2028 (before the final patient, which is scheduled for March 2028), so the company will still have to answer that financing question then.

… but that is more than 18 months away.

Immuron (ASX: IMC) has secured an exclusive agreement to distribute and sell its IBS powder product in the US with Swedish healthcare company Calmino. (IMC)

🪑  Nice announcement.

But can someone explain to me how a powder product can be registered as a “medical device”?

Stryker completed its first live surgery using the FDA-authorised using the SportsSuiteVision application for the Apple Vision Pro. (PR Newswire)

🪑  I thought this was interesting; the crossover between Big Tech/Wearables and medical applications is getting stronger and stronger.

Report: Big pharma eyes Australian biotech as $300b patent cliff looms. (AFR) 

🪑  Nice write-up on the healthcare sector by the AFR.

Two FDA consultations I’ll be watching in the next couple of weeks:

See you all tomorrow,

The Armchair Analyst